<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02312154</url>
  </required_header>
  <id_info>
    <org_study_id>KUH1120048</org_study_id>
    <nct_id>NCT02312154</nct_id>
  </id_info>
  <brief_title>Changing in Skin Physiology After Microdroplet Placement of Stabilized Hyaluronic Acid in Aging Faces</brief_title>
  <official_title>Split-face Study of Changing in Skin Physiology and Clinical Appearance After Microdroplet Placement of Stabilized Hyaluronic Acid in Aging Faces</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Konkuk University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Konkuk University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      IMPORTANCE Skin rejuvenation can be achieved effectively and safely by injection of a
      stabilized hyaluronic acid (HA)-based gel of nonanimal origin (NASHA) injection using a
      stamp-type electronic multineedle injector.

      OBJECTIVE To determine the efficacy and safety of NASHA using a stamp-type electronic
      multineedle injector, and if changes in skin physiology occur earlier than in previous
      trials.

      DESIGN, SETTING, AND PARTICIPANTS Twenty-five patients were recruited to this single-center,
      evaluator-blinded, prospective, balanced (1:1), split-face randomized clinical trial.One
      dermatologist who was blinded as to the treatment side evaluated the skin hydration, melanin
      content, erythema, and elasticity of both cheeks using a corneometer, a mexameter, and a
      reviscometer, respectively, at each follow-up visit (0, 1, 2, 4, 8, and 12 weeks
      postinjection). The subjects and two independent investigators assessed the clinical
      improvement using the Global Aesthetic Improvement Scale (GAIS) at the every visit.
      Twenty-four participants completed the study, and no participants withdrew due to adverse
      effects.

      INTERVENTIONS Each participant submitted to a single treatment with a NASHA injection to one
      side of the lower cheek. The cheek side to which the treatment was applied was chosen
      randomly.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty-five patients were recruited to this single-center, evaluator-blinded, prospective,
      balanced (1:1), split-face randomized clinical trial. Twenty-four participants completed the
      study, and no participants withdrew due to adverse effects. Each participant submitted to a
      single treatment with a NASHA injection to one side of the lower cheek. One dermatologist who
      was blinded as to the treatment side evaluated the skin hydration, melanin content, erythema,
      and elasticity of both cheeks using a corneometer, a mexameter, and a reviscometer,
      respectively, at each follow-up visit (0, 1, 2, 4, 8, and 12 weeks postinjection). The
      subjects and two independent investigators assessed the clinical improvement using the Global
      Aesthetic Improvement Scale (GAIS) at the every visit. Adverse events were self-reported by
      the patients completing a questionnaire.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hydration Level</measure>
    <time_frame>12 weeks</time_frame>
    <description>We measured a hydration level by a corneometer device (Courage &amp; Khazaka, Cologne, Germany).
The range of hydration level was 0 (as dry as possible) ~120 AU (Arbitrary Unit)(most moist possible)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elasticity</measure>
    <time_frame>12 weeks</time_frame>
    <description>We measured a elasticity by a reviscometer device (Courage &amp; Khazaka, Cologne, Germany).
The range of elasticity was 0 (most elastic possible as) ~400 AU(Arbitrary Unit) (inelastic as possible)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Melanin Index</measure>
    <time_frame>12 weeks</time_frame>
    <description>We measured a melanin index by a mexameter device (Courage &amp; Khazaka, Cologne, Germany).
The range of melanin index was 0 (as bright as possible) ~999 AU (Arbitrary Unit) (most dark possible).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Erythema Index</measure>
    <time_frame>12 weeks</time_frame>
    <description>We measured an erythema index by a mexameter device (Courage &amp; Khazaka, Cologne, Germany).
The range of erythema index is 0~999 AU(Arbitrary Unit). The range of erythema index was 0 (as non-erythematous as possible) ~999 AU (most erythematous possible)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Global Aesthetic Improvement Scale (Investigator)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The therapeutic outcome was assessed by investigator using the Global Aesthetic Improvement Scale (GAIS), which rates outcome on the following 5-point scale: 3, very much improved; 2, much improved; 1, improved; 0, no change; and -1, worse.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Global Aesthetic Improvement Scale (Subject)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The therapeutic outcome was assessed by patient self-assessment using the Global Aesthetic Improvement Scale (GAIS), which rates outcome on the following 5-point scale: 3, very much improved; 2, much improved; 1, improved; 0, no change; and -1, worse</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>treated side (Restylane vital)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>We injected staabilized hyaluronic acid (HA)-based gel of nonanimal origin on the left side of face.
(We performed split face study)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>untreated side (control)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>We did nothing on the right side of face and we compared the results on same participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Restylane Vital</intervention_name>
    <description>stabilized hyaluronic acid (HA)-based gel of nonanimal origin</description>
    <arm_group_label>treated side (Restylane vital)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy people older than 25 years

        Exclusion Criteria:

          -  known hypersensitivity to HA, an active skin disease, any autoimmune disorder, or
             significant renal, hepatic, or other medical diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yang Won Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology, Konkuk University School of Medicine, Seoul, Korea</affiliation>
  </overall_official>
  <reference>
    <citation>Gniadecka M, Nielsen OF, Wessel S, Heidenheim M, Christensen DH, Wulf HC. Water and protein structure in photoaged and chronically aged skin. J Invest Dermatol. 1998 Dec;111(6):1129-33.</citation>
    <PMID>9856828</PMID>
  </reference>
  <reference>
    <citation>Matarasso SL, Carruthers JD, Jewell ML; Restylane Consensus Group. Consensus recommendations for soft-tissue augmentation with nonanimal stabilized hyaluronic acid (Restylane). Plast Reconstr Surg. 2006 Mar;117(3 Suppl):3S-34S; discussion 35S-43S.</citation>
    <PMID>16531934</PMID>
  </reference>
  <reference>
    <citation>Kerscher M, Bayrhammer J, Reuther T. Rejuvenating influence of a stabilized hyaluronic acid-based gel of nonanimal origin on facial skin aging. Dermatol Surg. 2008 May;34(5):720-6. doi: 10.1111/j.1524-4725.2008.34176.x. Epub 2008 Apr 1.</citation>
    <PMID>18384619</PMID>
  </reference>
  <reference>
    <citation>Streker M, Reuther T, Krueger N, Kerscher M. Stabilized hyaluronic acid-based gel of non-animal origin for skin rejuvenation: face, hand, and décolletage. J Drugs Dermatol. 2013 Sep;12(9):990-4.</citation>
    <PMID>24002145</PMID>
  </reference>
  <reference>
    <citation>Naylor EC, Watson RE, Sherratt MJ. Molecular aspects of skin ageing. Maturitas. 2011 Jul;69(3):249-56. doi: 10.1016/j.maturitas.2011.04.011. Epub 2011 May 25. Review.</citation>
    <PMID>21612880</PMID>
  </reference>
  <reference>
    <citation>Distante F, Pagani V, Bonfigli A. Stabilized hyaluronic acid of non-animal origin for rejuvenating the skin of the upper arm. Dermatol Surg. 2009 Feb;35 Suppl 1:389-93; discussion 394. doi: 10.1111/j.1524-4725.2008.01051.x.</citation>
    <PMID>19207331</PMID>
  </reference>
  <reference>
    <citation>Williams S, Tamburic S, Stensvik H, Weber M. Changes in skin physiology and clinical appearance after microdroplet placement of hyaluronic acid in aging hands. J Cosmet Dermatol. 2009 Sep;8(3):216-25. doi: 10.1111/j.1473-2165.2009.00447.x.</citation>
    <PMID>19735521</PMID>
  </reference>
  <reference>
    <citation>Reuther T, Bayrhammer J, Kerscher M. Effects of a three-session skin rejuvenation treatment using stabilized hyaluronic acid-based gel of non-animal origin on skin elasticity: a pilot study. Arch Dermatol Res. 2010 Jan;302(1):37-45. doi: 10.1007/s00403-009-0988-9.</citation>
    <PMID>19730872</PMID>
  </reference>
  <reference>
    <citation>Ribé A, Ribé N. Neck skin rejuvenation: histological and clinical changes after combined therapy with a fractional non-ablative laser and stabilized hyaluronic acid-based gel of non-animal origin. J Cosmet Laser Ther. 2011 Aug;13(4):154-61. doi: 10.3109/14764172.2011.594060. Epub 2011 Jun 23.</citation>
    <PMID>21699363</PMID>
  </reference>
  <reference>
    <citation>Tezel A, Fredrickson GH. The science of hyaluronic acid dermal fillers. J Cosmet Laser Ther. 2008 Mar;10(1):35-42. doi: 10.1080/14764170701774901. Review. Erratum in: J Cosmet Laser Ther. 2014 Jan;16(1):45.</citation>
    <PMID>18330796</PMID>
  </reference>
  <reference>
    <citation>Wang F, Garza LA, Kang S, Varani J, Orringer JS, Fisher GJ, Voorhees JJ. In vivo stimulation of de novo collagen production caused by cross-linked hyaluronic acid dermal filler injections in photodamaged human skin. Arch Dermatol. 2007 Feb;143(2):155-63.</citation>
    <PMID>17309996</PMID>
  </reference>
  <reference>
    <citation>Alam M, Han S, Pongprutthipan M, Disphanurat W, Kakar R, Nodzenski M, Pace N, Kim N, Yoo S, Veledar E, Poon E, West DP. Efficacy of a needling device for the treatment of acne scars: a randomized clinical trial. JAMA Dermatol. 2014 Aug;150(8):844-9. doi: 10.1001/jamadermatol.2013.8687.</citation>
    <PMID>24919799</PMID>
  </reference>
  <reference>
    <citation>Kim SE, Lee JH, Kwon HB, Ahn BJ, Lee AY. Greater collagen deposition with the microneedle therapy system than with intense pulsed light. Dermatol Surg. 2011 Mar;37(3):336-41. doi: 10.1111/j.1524-4725.2011.01882.x. Epub 2011 Feb 22.</citation>
    <PMID>21342311</PMID>
  </reference>
  <reference>
    <citation>Lim HK, Suh DH, Lee SJ, Shin MK. Rejuvenation effects of hyaluronic acid injection on nasojugal groove: prospective randomized split face clinical controlled study. J Cosmet Laser Ther. 2014 Jan;16(1):32-6. doi: 10.3109/14764172.2013.854620. Epub 2013 Nov 19.</citation>
    <PMID>24245880</PMID>
  </reference>
  <reference>
    <citation>Bachmann F, Erdmann R, Hartmann V, Wiest L, Rzany B. The spectrum of adverse reactions after treatment with injectable fillers in the glabellar region: results from the Injectable Filler Safety Study. Dermatol Surg. 2009 Oct;35 Suppl 2:1629-34. doi: 10.1111/j.1524-4725.2009.01341.x.</citation>
    <PMID>19807757</PMID>
  </reference>
  <reference>
    <citation>Kassir R, Kolluru A, Kassir M. Extensive necrosis after injection of hyaluronic acid filler: case report and review of the literature. J Cosmet Dermatol. 2011 Sep;10(3):224-31. doi: 10.1111/j.1473-2165.2011.00562.x. Review.</citation>
    <PMID>21896135</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2014</study_first_submitted>
  <study_first_submitted_qc>December 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2014</study_first_posted>
  <results_first_submitted>December 9, 2014</results_first_submitted>
  <results_first_submitted_qc>February 20, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 24, 2015</results_first_posted>
  <last_update_submitted>March 16, 2015</last_update_submitted>
  <last_update_submitted_qc>March 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Konkuk University Hospital</investigator_affiliation>
    <investigator_full_name>Yang Won Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Restylane Vital</title>
          <description>stabilized hyaluronic acid (HA)-based gel of nonanimal origin
Restylane Vital: stabilized hyaluronic acid (HA)-based gel of nonanimal origin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Restylane Vital</title>
          <description>stabilized hyaluronic acid (HA)-based gel of nonanimal origin
Restylane Vital: stabilized hyaluronic acid (HA)-based gel of nonanimal origin</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>20-29 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30-39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40-49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50-59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>hydration</title>
          <description>We measured a hydration level by a combination corneometer/mexameter/reviscometer device (Courage &amp; Khazaka, Cologne, Germany).
The range of hydration level was 0~120 AU(Arbitrary Unit).
&lt; 30 : Very dry, 30~49 : Dry, 50~59: Moisturized, &gt;60 : Sufficiently Moisturized</description>
          <units>AU (Arbitrary Unit)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>treated side</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.47" spread="10.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>untreated side</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.21" spread="11.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>elasticity</title>
          <description>We measured a elasticity by a combination corneometer/mexameter/reviscometer device (Courage &amp; Khazaka, Cologne, Germany).
The range of elasticity is 0~400 AU(Arbitrary Unit). The lower revisometer values reflect higher elasticity.</description>
          <units>AU (arbitrary unit)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>treated side</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="294.32" spread="90.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>untreated side</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="272.70" spread="96.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>melanin index</title>
          <description>We measured a melanin index by a combination corneometer/mexameter/reviscometer device (Courage &amp; Khazaka, Cologne, Germany).
The range of melamin index is 0~999 AU(Arbitrary Unit).
0~49: Phototype I (celtic type), 50~99 : Phototype II (Caucasian type), 100~149 : Phototype III (European mixed type), 150~199 : Phototype IV (Mediterranean type), 200~299 : Phototype V (Asian/Indian type), 300~999 : Phototype VI (Black skin type) (This is only an approach. It is recommend that each user should develop an own interpretation scale.)</description>
          <units>AU(arbitrary unit)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>treated side</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133.97" spread="25.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>untreated side</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133.66" spread="27.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>erythema index</title>
          <description>We measured a erythema index by a combination corneometer/mexameter/reviscometer device (Courage &amp; Khazaka, Cologne, Germany).
The range of erythema index is 0~999 AU(Arbitrary Unit). The lower erythema indices than baseline reflect improvement of erythema.</description>
          <units>AU(arbitrary unit)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>treated side</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="292.74" spread="71.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>untreated side</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="290.50" spread="59.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hydration Level</title>
        <description>We measured a hydration level by a corneometer device (Courage &amp; Khazaka, Cologne, Germany).
The range of hydration level was 0 (as dry as possible) ~120 AU (Arbitrary Unit)(most moist possible)</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treated Side (Restylane Vital)</title>
            <description>stabilized hyaluronic acid (HA)-based gel of nonanimal origin
Restylane Vital: stabilized hyaluronic acid (HA)-based gel of nonanimal origin</description>
          </group>
          <group group_id="O2">
            <title>Untreated Side</title>
            <description>Eligible patients received injections of NASHA into the dermis on one side of the lower part of the cheek in a single session, at the start of the study (visit 1); the other side was left untreated.</description>
          </group>
        </group_list>
        <measure>
          <title>Hydration Level</title>
          <description>We measured a hydration level by a corneometer device (Courage &amp; Khazaka, Cologne, Germany).
The range of hydration level was 0 (as dry as possible) ~120 AU (Arbitrary Unit)(most moist possible)</description>
          <units>AU (arbitrary unit)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.19" spread="9.08"/>
                    <measurement group_id="O2" value="46.75" spread="9.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The change in each of the biophysical parameters was calculated as the pretreatment value minus the posttreatment value for each visit, and these pre- vs posttreatment changes were used in the statistical analysis to minimize the intraindividual variation between the two cheeks. The Wilcoxon rank-sum test was performed to compare the week-by-week changes in parameters of the right and left cheeks (i.e., treated vs untreated).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Elasticity</title>
        <description>We measured a elasticity by a reviscometer device (Courage &amp; Khazaka, Cologne, Germany).
The range of elasticity was 0 (most elastic possible as) ~400 AU(Arbitrary Unit) (inelastic as possible)</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treated Side (Restylane Vital)</title>
            <description>stabilized hyaluronic acid (HA)-based gel of nonanimal origin
Restylane Vital: stabilized hyaluronic acid (HA)-based gel of nonanimal origin</description>
          </group>
          <group group_id="O2">
            <title>Untreated Side</title>
            <description>Eligible patients received injections of NASHA into the dermis on one side of the lower part of the cheek in a single session, at the start of the study (visit 1); the other side was left untreated.</description>
          </group>
        </group_list>
        <measure>
          <title>Elasticity</title>
          <description>We measured a elasticity by a reviscometer device (Courage &amp; Khazaka, Cologne, Germany).
The range of elasticity was 0 (most elastic possible as) ~400 AU(Arbitrary Unit) (inelastic as possible)</description>
          <units>AU (arbitrary unit)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="242.33" spread="72.21"/>
                    <measurement group_id="O2" value="271.15" spread="86.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The change in each of the biophysical parameters was calculated as the pretreatment value minus the posttreatment value for each visit, and these pre- vs posttreatment changes were used in the statistical analysis to minimize the intraindividual variation between the two cheeks. The Wilcoxon rank-sum test was performed to compare the week-by-week changes in parameters of the right and left cheeks (i.e., treated vs untreated).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Melanin Index</title>
        <description>We measured a melanin index by a mexameter device (Courage &amp; Khazaka, Cologne, Germany).
The range of melanin index was 0 (as bright as possible) ~999 AU (Arbitrary Unit) (most dark possible).</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treated Side (Restylane Vital)</title>
            <description>stabilized hyaluronic acid (HA)-based gel of nonanimal origin
Restylane Vital: stabilized hyaluronic acid (HA)-based gel of nonanimal origin</description>
          </group>
          <group group_id="O2">
            <title>Untreated Side</title>
            <description>Eligible patients received injections of NASHA into the dermis on one side of the lower part of the cheek in a single session, at the start of the study (visit 1); the other side was left untreated.</description>
          </group>
        </group_list>
        <measure>
          <title>Melanin Index</title>
          <description>We measured a melanin index by a mexameter device (Courage &amp; Khazaka, Cologne, Germany).
The range of melanin index was 0 (as bright as possible) ~999 AU (Arbitrary Unit) (most dark possible).</description>
          <units>AU (arbitrary unit)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147.25" spread="27.46"/>
                    <measurement group_id="O2" value="149.00" spread="26.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The change in each of the biophysical parameters was calculated as the pretreatment value minus the posttreatment value for each visit, and these pre- vs posttreatment changes were used in the statistical analysis to minimize the intraindividual variation between the two cheeks. The Wilcoxon rank-sum test was performed to compare the week-by-week changes in parameters of the right and left cheeks (i.e., treated vs untreated).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Erythema Index</title>
        <description>We measured an erythema index by a mexameter device (Courage &amp; Khazaka, Cologne, Germany).
The range of erythema index is 0~999 AU(Arbitrary Unit). The range of erythema index was 0 (as non-erythematous as possible) ~999 AU (most erythematous possible)</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treated Side (Restylane Vital)</title>
            <description>stabilized hyaluronic acid (HA)-based gel of nonanimal origin
Restylane Vital: stabilized hyaluronic acid (HA)-based gel of nonanimal origin</description>
          </group>
          <group group_id="O2">
            <title>Untreated Side</title>
            <description>Eligible patients received injections of NASHA into the dermis on one side of the lower part of the cheek in a single session, at the start of the study (visit 1); the other side was left untreated.</description>
          </group>
        </group_list>
        <measure>
          <title>Erythema Index</title>
          <description>We measured an erythema index by a mexameter device (Courage &amp; Khazaka, Cologne, Germany).
The range of erythema index is 0~999 AU(Arbitrary Unit). The range of erythema index was 0 (as non-erythematous as possible) ~999 AU (most erythematous possible)</description>
          <units>AU (arbitrary unit)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253.66" spread="58.19"/>
                    <measurement group_id="O2" value="243.53" spread="51.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The change in each of the biophysical parameters was calculated as the pretreatment value minus the posttreatment value for each visit, and these pre- vs posttreatment changes were used in the statistical analysis to minimize the intraindividual variation between the two cheeks. The Wilcoxon rank-sum test was performed to compare the week-by-week changes in parameters of the right and left cheeks (i.e., treated vs untreated).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Global Aesthetic Improvement Scale (Investigator)</title>
        <description>The therapeutic outcome was assessed by investigator using the Global Aesthetic Improvement Scale (GAIS), which rates outcome on the following 5-point scale: 3, very much improved; 2, much improved; 1, improved; 0, no change; and -1, worse.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treated Side (Restylane Vital)</title>
            <description>stabilized hyaluronic acid (HA)-based gel of nonanimal origin
Restylane Vital: stabilized hyaluronic acid (HA)-based gel of nonanimal origin</description>
          </group>
          <group group_id="O2">
            <title>Untreated Side</title>
            <description>Eligible patients received injections of NASHA into the dermis on one side of the lower part of the cheek in a single session, at the start of the study (visit 1); the other side was left untreated.</description>
          </group>
        </group_list>
        <measure>
          <title>Global Aesthetic Improvement Scale (Investigator)</title>
          <description>The therapeutic outcome was assessed by investigator using the Global Aesthetic Improvement Scale (GAIS), which rates outcome on the following 5-point scale: 3, very much improved; 2, much improved; 1, improved; 0, no change; and -1, worse.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" spread="0.77"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The therapeutic outcome was assessed by patient self-assessment using the Global Aesthetic Improvement Scale, which rates outcome on the following 5-point scale: 3, very much improved; 2, much improved; 1, improved; 0, no change; and –1, worse. Two independent investigators also individually assessed every patient’s improvement, and the values of the two scores were averaged for each patient. The Wilcoxon rank-sum test was performed to compare the pre-by-posttreatment changes in treated side.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Global Aesthetic Improvement Scale (Subject)</title>
        <description>The therapeutic outcome was assessed by patient self-assessment using the Global Aesthetic Improvement Scale (GAIS), which rates outcome on the following 5-point scale: 3, very much improved; 2, much improved; 1, improved; 0, no change; and -1, worse</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treated Side (Restylane Vital)</title>
            <description>stabilized hyaluronic acid (HA)-based gel of nonanimal origin
Restylane Vital: stabilized hyaluronic acid (HA)-based gel of nonanimal origin</description>
          </group>
          <group group_id="O2">
            <title>Untreated Side</title>
            <description>Eligible patients received injections of NASHA into the dermis on one side of the lower part of the cheek in a single session, at the start of the study (visit 1); the other side was left untreated.</description>
          </group>
        </group_list>
        <measure>
          <title>Global Aesthetic Improvement Scale (Subject)</title>
          <description>The therapeutic outcome was assessed by patient self-assessment using the Global Aesthetic Improvement Scale (GAIS), which rates outcome on the following 5-point scale: 3, very much improved; 2, much improved; 1, improved; 0, no change; and -1, worse</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="1.05"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The therapeutic outcome was assessed by patient self-assessment using the Global Aesthetic Improvement Scale, which rates outcome on the following 5-point scale: 3, very much improved; 2, much improved; 1, improved; 0, no change; and –1, worse. Two independent investigators also individually assessed every patient’s improvement, and the values of the two scores were averaged for each patient. The Wilcoxon rank-sum test was performed to compare the pre-by-posttreatment changes in treated side.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12weeks</time_frame>
      <desc>Adverse events were self-reported by the patients completing a questionnaire.</desc>
      <group_list>
        <group group_id="E1">
          <title>Restylane Vital</title>
          <description>stabilized hyaluronic acid (HA)-based gel of nonanimal origin
Restylane Vital: stabilized hyaluronic acid (HA)-based gel of nonanimal origin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>erythema</sub_title>
                <description>Erythema developed right after the treatment and maintained until 5days after the treatment</description>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>First, it did not have a double-blind design, and so the GAIS scores of the subjects could have been influenced. Second, the posttreatment follow-up period was relatively short, at 12 weeks. Finally, the patient sample in this study was small.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Yang Won Lee</name_or_title>
      <organization>Konkuk University</organization>
      <phone>8220305172</phone>
      <email>20130112@kuh.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

